Capital International Investors
ONC

Capital International Investors’s BeOne Medicines Ltd ONC Stock Holding History

Capital International Investors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23B Sell
4,158,726
-955,140
-19% -$309M 0.29% 83
2025
Q4 		$1.55B Buy
5,113,866
+67,808
+1% +$22.2M 0.24% 83
2025
Q3 		$1.72B Buy
5,046,058
+161,052
+3% +$48.9M 0.28% 81
2025
Q2 		$1.18B Sell
4,885,006
-205,964
-4% -$50.5M 0.2% 103
2025
Q1 		$1.38B Sell
5,090,970
-1,022,195
-17% -$239M 0.27% 91
2024
Q4 		$1.13B Sell
6,113,165
-317,719
-5% -$64.9M 0.21% 101
2024
Q3 		$1.44B Sell
6,430,884
-582,684
-8% -$105M 0.28% 84
2024
Q2 		$1B Sell
7,013,568
-50,860
-0.7% -$7.84M 0.21% 104
2024
Q1 		$1.1B Buy
7,064,428
+727,556
+11% +$117M 0.22% 103
2023
Q4 		$1.14B Buy
6,336,872
+285,397
+5% +$51.6M 0.26% 99
2023
Q3 		$1.09B Sell
6,051,475
-243,924
-4% -$48.3M 0.28% 90
2023
Q2 		$1.12B Sell
6,295,399
-270,200
-4% -$62.2M 0.27% 91
2023
Q1 		$1.42B Sell
6,565,599
-211,846
-3% -$50.8M 0.36% 78
2022
Q4 		$1.49B Buy
6,777,445
+186,203
+3% +$34.1M 0.4% 73
2022
Q3 		$889M Sell
6,591,242
-213,048
-3% -$36.6M 0.26% 98
2022
Q2 		$1.1B Sell
6,804,290
-251,005
-4% -$39.2M 0.3% 90
2022
Q1 		$1.34B Buy
7,055,295
+711,396
+11% +$151M 0.3% 88
2021
Q4 		$1.72B Buy
6,343,899
+19,980
+0.3% +$6.75M 0.36% 75
2021
Q3 		$2.3B Buy
6,323,919
+384,269
+6% +$126M 0.52% 50
2021
Q2 		$2.04B Buy
5,939,650
+142,499
+2% +$47.2M 0.47% 56
2021
Q1 		$2.01B Buy
5,797,151
+428,521
+8% +$142M 0.51% 50
2020
Q4 		$1.39B Sell
5,368,630
-593,750
-10% -$163M 0.38% 75
2020
Q3 		$1.71B Buy
5,962,380
+8,945
+0.2% +$2.1M 0.53% 47
2020
Q2 		$1.12B Buy
5,953,435
+246,826
+4% +$40.2M 0.37% 69
2020
Q1 		$703M Buy
5,706,609
+1,155,679
+25% +$181M 0.29% 89
2019
Q4 		$754M Buy
4,550,930
+998,037
+28% +$166M 0.26% 113
2019
Q3 		$435M Buy
3,552,893
+1,082,594
+44% +$144M 0.17% 137
2019
Q2 		$306M Buy
2,470,299
+626,368
+34% +$79.5M 0.12% 163
2019
Q1 		$593M Buy
1,843,931
+818,425
+80% +$110M 0.25% 104
2018
Q4 		$144M Buy
+1,025,506
New +$136M 0.07% 186

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Capital International Investors's ONC Position: Q1 2026 in Review

Capital International Investors reduced its BeOne Medicines Ltd (ONC) stake by 19% in Q1 2026, selling an estimated $309M and leaving 4,158,726 shares worth $1.23B. The position accounts for 0.29% of the portfolio, ranked #83.

Capital International Investors first reported a position in ONC in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.3B in Q3 2021. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Capital International Investors held 4,158,726 shares of BeOne Medicines Ltd worth $1.23B as of Q1 2026.
  • Capital International Investors sold 955,140 BeOne Medicines Ltd shares in Q1 2026, an estimated $309M.
  • BeOne Medicines Ltd made up 0.29% of Capital International Investors's portfolio in Q1 2026, its #83 holding.
  • Capital International Investors first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 30 quarters since.
  • Capital International Investors's BeOne Medicines Ltd position peaked at $2.3B in Q3 2021.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Capital International Investors's 13F filing for Q1 2026, filed 13 May 2026.